To review the current evidence on how the gut microbiome influences triple-negative breast cancer (TNBC) biology, particularly regarding the immune microenvironment, treatment responses, and potential therapeutic interventions.
Key Findings:
Dysbiosis is linked to cancer initiation, progression, and therapy resistance in TNBC.
Higher microbial diversity and SCFA-producing taxa are associated with improved treatment responses.
Obesity and antibiotic exposure contribute to dysbiosis, leading to chronic inflammation and worse outcomes.
Distinct intratumoral microbiomes may influence local immune responses and tumor dynamics.
Interpretation:
The gut microbiome plays a significant role in regulating immune responses and treatment efficacy in TNBC, suggesting potential avenues for therapeutic intervention.
Limitations:
The review does not provide direct clinical trial data linking microbiome interventions to TNBC outcomes, which limits the applicability of findings.
Further research is needed to establish causative relationships between microbiome alterations and TNBC progression, particularly in clinical settings.
Conclusion:
Understanding the gut microbiome's impact on TNBC may lead to improved management strategies and patient outcomes, including potential microbiome-targeted therapies.
